Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cha Biolab Co. Ltd. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and is being processed within 1 distinct art unit. This concentration indicates that the company's current active prosecution is focused on a specific technical niche that falls under a single administrative group at the patent office. Such a profile allows for a very direct and singular legal strategy for the company's pending intellectual property.
The busiest examiner for this portfolio is GRABER, JAMES J, who is responsible for 1 pending office action. Since there is only 1 active matter in total, this examiner handles the entirety of the company's current workload. The alignment of 1 examiner and 1 art unit for the pending action means that the outcome of the company's filing is entirely dependent on the review of this single individual. For practitioners, this singular alignment across all metrics simplifies the monitoring of prosecution trends within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRABER, JAMES J | 1 | 46.7% | +57.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18300852 | NATURAL KILLER CELL HAVING CONTROLLED ONCOLOGY-RELEATED GENE EXPRESSION, AND USE THEREOF | GRABER, JAMES J | 34d |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18300852 | NATURAL KILLER CELL HAVING CONTROLLED ONCOLOGY-RELEATED GENE EXPRESSION, AND USE THEREOF | GRABER, JAMES J | 1631 | §103 | Final Rejection | 34d | Pending | Apr 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial